according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Carcinogenicity (Inhalation) : Category 2

Specific target organ toxicity - repeated exposure (Oral)

Category 2 (Liver, Testis)

GHS label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H351 Suspected of causing cancer if inhaled.

H373 May cause damage to organs (Liver, Testis) through pro-

longed or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 07/06/2024 76219-00028 Date of first issue: 03/17/2015 14.0

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 5 - < 10
Grazoprevir	1350462-55-3	>= 5 - < 10
Elbasvir	1370468-36-2	>= 1 - < 5
Magnesium stearate	557-04-0	>= 1 - < 5
Titanium dioxide	13463-67-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

Protection of first-aiders

delayed

Suspected of causing cancer if inhaled. May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

: Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides Metal oxides

Chlorine compounds Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Use only with adequate ventilation.

Do not breathe dust. Advice on safe handling Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 ma/m³

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m³

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

10 mg/m³

ticulates Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/06/2024

 14.0
 07/06/2024
 76219-00028
 Date of first issue: 03/17/2015

		exposure)	concentration	
Cellulose	9004-34-6	TWA	10 mg/m³	ACGIH
		TWA (Res-	5 mg/m³	NIOSH REL
		pirable)		
		TWA (total)	10 mg/m³	NIOSH REL
		TWA (total	15 mg/m³	OSHA Z-1
		dust)		
		TWA (respir-	5 mg/m³	OSHA Z-1
		able fraction)		
Grazoprevir	1350462-55-	TWA	85 μg/m3 (OEB 3)	Internal
	3			
		Wipe limit	850 µg/100 cm ²	Internal
Elbasvir	1370468-36-	TWA	150 μg/m3 (OEB	Internal
	2		2)	
Magnesium stearate	557-04-0	TWA (Inhal-	10 mg/m³	ACGIH
		able particu-		
		late matter)		
		TWA (Res-	3 mg/m³	ACGIH
		pirable par-		
		ticulate mat-		
	10.100.05 =	ter)	1.5	00114 7 4
Titanium dioxide	13463-67-7	TWA (total	15 mg/m³	OSHA Z-1
		dust)		

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Grazoprevir:

Result : No skin irritation

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Elbasvir:

Species : reconstructed human epidermis (RhE)

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Grazoprevir:

Species : Bovine cornea Result : No eye irritation

Elbasvir:

Species : Bovine cornea Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Grazoprevir:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Dermal

Result : Not a skin sensitizer.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Elbasvir:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Dermal Species : Mouse Result : negative

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

П

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Rat

Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Titanium dioxide:

Species : Rat

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : positive

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in inhalation studies with

animals.

IARC Group 2B: Possibly carcinogenic to humans

Titanium dioxide 13463-67-7

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Grazoprevir:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: negative

Test Type: Multi-generation study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: No effects on fertility., No effects on fetal development.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight

Result: No effects on fetal development.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight

Result: No effects on fetal development.

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous

Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight

Result: No effects on fetal development.

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on early embryonic development.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Result: No effects on early embryonic development.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development: Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Components:

Grazoprevir:

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL >= 9,000 mg/kgApplication Route : Ingestion Exposure time : 90 Days

Grazoprevir:

Species Rat NOAEL 400 mg/kg Application Route Oral Exposure time 30 Days

Remarks : No significant adverse effects were reported

Species Rat NOAEL Application Route Exposure time 400 mg/kg Oral 180 Days

Remarks No significant adverse effects were reported

Species Dog NOAEL 15 mg/kg NOAEL LOAEL Application Route Exposure time Target Organs 100 mg/kg Oral : 270 Days

Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species Mouse NOAEL 200 mg/kg LOAEL : 500 mg/kg Application Route : Oral Exposure time 90 Days

Target Organs Liver, Kidney, Blood

Species Dog NOAEL 20 mg/kg LOAEL 600 mg/kg Application Route Oral Exposure time 30 Days

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Target Organs : Blood, Testis

Species : Monkey
NOAEL : 10 mg/kg
Exposure time : 8 Days

Remarks : No significant adverse effects were reported

Elbasvir:

Species : Rat

NOAEL : 1,000 mg/kg

Application Route : Oral Exposure time : 180 d

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 1,000 mg/kg Application Route : Oral

Exposure time : Oral : 270 d

Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat

NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat NOAEL : 10 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea,

Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irrita-

tion, rhinitis, Drowsiness, nasal congestion

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Grazoprevir:

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10

mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 8.9 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 10

ma/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 10

mg/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 5 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1.3 mg/l Exposure time: 3 h

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

> Test Type: Respiration inhibition Method: OECD Test Guideline 209

Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility.

LC50 (Menidia beryllina (Silverside)): > 10 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 7.7 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.84 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 271.9 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 07/06/2024 76219-00028 Date of first issue: 03/17/2015 14.0

Magnesium stearate:

Toxicity to fish LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

> Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

aquatic invertebrates

Toxicity to daphnia and other : EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

ma/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

EC10 (Pseudomonas putida): > 100 mg/l Toxicity to microorganisms

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

Biodegradability Result: Readily biodegradable.

Grazoprevir:

Result: Not readily biodegradable. Biodegradability

Biodegradation: 66 % Exposure time: 28 d

Elbasvir:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 37 % Exposure time: 28 d

Magnesium stearate:

Biodegradability Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Grazoprevir:

Species: Lepomis macrochirus (Bluegill sunfish) Bioaccumulation

Bioconcentration factor (BCF): 7.62

Partition coefficient: n-

octanol/water

: log Pow: 3.72

Elbasvir:

Species: Lepomis macrochirus (Bluegill sunfish) Bioaccumulation

> Bioconcentration factor (BCF): 82 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 6.54

Magnesium stearate:

Partition coefficient: n-

: log Pow: > 4

octanol/water

Mobility in soil

Components:

Grazoprevir:

Distribution among environ- : log Koc: 4.01

mental compartments

Elbasvir:

Distribution among environ- : log Koc: 5.24

mental compartments

Other adverse effects

No data available

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Elbasvir)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Elbasvir)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen: 956

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Elbasvir)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

(Elbasvir)

Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171

Marine pollutant : yes(Elbasvir)

Remarks : Above applies only to containers over 119 gallons or 450

liters.

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Carcinogenicity

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-mannitol	69-65-8
Hydroxypropyl methylcellulose	9004-65-3
Croscarmellose sodium	74811-65-7
Sodium chloride	7647-14-5
Polyvinylpyrolidone / Vinyl Acetate Copolymer	25086-89-9
Cellulose	9004-34-6
D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5
Grazoprevir	1350462-55-3
Elbasvir	1370468-36-2

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 14.0 07/06/2024 76219-00028 Date of first issue: 03/17/2015

California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6 Magnesium stearate 557-04-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

Flammability Health O Instability

Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

according to the OSHA Hazard Communication Standard



Grazoprevir / Elbasvir Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/06/2024

 14.0
 07/06/2024
 76219-00028
 Date of first issue: 03/17/2015

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 07/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8